Reuters logo
BRIEF-Redhill Biopharma announces positive results from phase 2 study of Bekinda in patients with irritable bowel syndrome (IBS-D)
October 3, 2017 / 11:14 AM / 16 days ago

BRIEF-Redhill Biopharma announces positive results from phase 2 study of Bekinda in patients with irritable bowel syndrome (IBS-D)

Oct 3 (Reuters) - Redhill Biopharma Ltd:

* Redhill Biopharma announces positive top-line results from phase II study of bekinda® in patients with diarrhea-predominant irritable bowel syndrome (IBS-D)

* Redhill Biopharma Ltd - ‍Bekinda®(i) 12 mg phase II study successfully met its primary endpoint​

* Redhill Biopharma- intends to pursue phase III studies with bekinda 12 mg, plans to meet with FDA by early 2018

* Redhill Biopharma Ltd says ‍bekinda 12 mg was also shown to be safe and well tolerated​

* Redhill-After successful first phase 3 study, positive guidance meeting with FDA, co designing confirmatory phase 3 study to support NDA for Bekinda 24​

* Redhill Biopharma Ltd - ‍completion of clinical study report expected in Q1 of 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below